CCP
ROIV icon

Clough Capital Partners’s Roivant Sciences ROIV Stock Holding History

Clough Capital Partners’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-34,300
Closed -$387K – 141
2025
Q2 		$387K Hold
34,300
– – 0.04% 114
2025
Q1 		$346K Hold
34,300
– – 0.04% 104
2024
Q4 		$406K Sell
34,300
-53,907
-61% -$637K 0.05% 112
2024
Q3 		$1.02M Sell
88,207
-288,730
-77% -$3.29M 0.1% 100
2024
Q2 		$3.98M Sell
376,937
-291,618
-44% -$3.2M 0.44% 57
2024
Q1 		$7.05M Sell
668,555
-10,105
-1% -$109K 0.77% 47
2023
Q4 		$7.62M Sell
678,660
-44,140
-6% -$430K 0.84% 40
2023
Q3 		$8.44M Buy
722,800
+215,300
+42% +$2.43M 0.91% 41
2023
Q2 		$5.12M Buy
+507,500
New +$4.54M 0.51% 62

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PSC
Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return

Clough Capital Partners's ROIV Position: Q3 2025 in Review

Clough Capital Partners sold out of Roivant Sciences (ROIV) in Q3 2025, closing a stake of 34,300 shares — an estimated $387K sold.

Clough Capital Partners first reported a position in ROIV in Q2 2023 and held it in 9 quarters. The position peaked at $8.44M in Q3 2023. 337 funds tracked by Wall St. Rank hold ROIV as of Q3 2025.

  • Clough Capital Partners reported no remaining Roivant Sciences position as of Q3 2025 after selling out during the quarter.
  • Clough Capital Partners sold 34,300 Roivant Sciences shares in Q3 2025, an estimated $387K.
  • Clough Capital Partners first reported a position in Roivant Sciences in Q2 2023 and held it in 9 quarters.
  • Clough Capital Partners's Roivant Sciences position peaked at $8.44M in Q3 2023.
  • 337 funds tracked by Wall St. Rank held Roivant Sciences as of Q3 2025.

Based on Clough Capital Partners's 13F filing for Q3 2025, filed 14 Nov 2025.